Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Congenital Herpes Virus Tied to Common Childhood Cancer

By LabMedica International staff writers
Posted on 05 Jan 2017
Childhood acute lymphoblastic leukemia develops when the bone marrow makes too many immature white blood cells, stem cells that become lymphoblasts, B lymphocytes, or T lymphocytes.

It is widely suspected, yet controversial, that infection plays an etiologic role in the development of acute lymphoblastic leukemia (ALL), the most common childhood cancer and a disease with a confirmed prenatal origin in most cases. Children who develop ALL are over three times more likely to have tested positive for the common herpes virus cytomegalovirus (CMV) at birth.

Scientists at the University of California (Berkeley, CA, USA) and their colleagues first compared bone marrow infections in 127 children diagnosed with ALL, and in 38 children diagnosed with another type of leukemia, acute myeloid leukemia (AML). They used state-of-the-art methods to screen the samples for all known viruses and bacteria. They then used an ultra-sensitive digital droplet screen to test for CMV in newborn blood samples of 268 children who went on to develop ALL. They also tested newborn blood samples from 270 healthy children.

The team found genetic traces of CMV in abnormal white blood cells and intact virus particles in blood samples in the children with ALL, but rarely in those with AML. They found that the children who went on to develop ALL were 3.71 times more likely to be CMV-positive at birth. The odds were higher for Hispanic children who developed ALL as they were 5.9 times more likely to be CMV-positive at birth. They demonstrated active viral transcription in leukemia blasts as well as intact virions in serum.

Stephen S. Francis, PhD, an assistant professor and first author of the study said, “"If it's truly that in-utero CMV is one of the initiating events in the development of childhood leukemia, then control of the virus has the potential to be a prevention target. That's the real take-home message.” The study was published on December 15, 2016, in the journal Blood.

Related Links:
University of California


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
High Performance Centrifuge
CO336/336R
New
Immunofluorescence Analyzer
MPQuanti
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.